Bangkok: The first batch of the royally bestowed cancer medication, "Imcranib 100," has been delivered to the Government Pharmaceutical Organization (GPO). It will be distributed to hospitals nationwide, ensuring that patients with universal healthcare coverage have equal access to the medication.
According to Thai News Agency, Ms. Ploytalay Laksmisangchan, Deputy Spokesperson for the Prime Minister's Office, revealed that through the immeasurable graciousness of Her Royal Highness Princess Chulabhorn Walailak, Krom Phra Srisavangavadhana, President and Chairperson of the Chulabhorn Royal Academy, 690,000 tablets of the targeted cancer medication Imcranib 100 have been graciously donated to the National Health Security Office (NHSO) on the occasion of her 69th birthday on July 4, 2026, under the Royal Commemoration Cancer Treatment Project.
Ms. Ploytalee stated that on June 2, 2026, the Pharmaceutical Manufacturing Plant under the Royal Initiative of Chulabhorn Royal Academy successfully produced and delivered the first batch of medication for the National Health Security Office (NHSO) to the Government Pharmaceutical Organization (GPO) distribution center, which serves as the NHSO's primary distribution hub. All warehousing and delivery operations were conducted under strict adherence to Good Distribution Practice (GDP) standards, ensuring the highest quality and safety of the medication until it reaches patients. Subsequently, the GPO will take over the distribution of Icranib 100 to healthcare facilities and hospitals nationwide, according to the NHSO's distribution plan, to ensure that patients under the universal health coverage system have equitable access to modern medications.
Icranib 100, a targeted cancer drug in tablet form, is a targeted therapy that inhibits the activity of the enzyme tyrosine kinase. This can suppress the growth and spread of cancer cells, leading to effective disease control with fewer side effects compared to traditional chemotherapy. It can be used to treat several types of cancer, including chronic myeloid leukemia (CML), acute myeloid leukemia with Philadelphia chromosomal positive (Ph+ ALL), gastrointestinal stromal tumors (GIST), and rare skin cancers (DFSP). This first-batch delivery marks another significant step in advancing Thailand's public health system, in line with His Majesty's unwavering commitment to overcoming economic barriers, improving quality of life, and providing equal access to modern treatment for all Thai citizens.